Abstract:Protein kinases regulate cellular activities and make up over 60% of oncoproteins and proto-oncoproteins. Among these kinases, FLT3 is a member of class III receptor tyrosine kinase family which is abundantly expressed in individuals with acute leukemia. Our previous oxindole-based hit has a particular affinity toward FLT3 (IC50 = 2.49 μM) and has demonstrated selectivity towards FLT3 ITD-mutated MV4-11 AML cells, with an IC50 of 4.3 μM. By utilizing the scaffold of the previous hit, sixteen new compounds were synthesized and screened against NCI-60 human cancer cell lines. This leads to the discovery of a potent antiproliferative compound, namely 5l, with an average GI50 value against leukemia and colon cancer subpanels equalling 3.39 and 5.97 μM, respectively. Screening against a specific set of 10 kinases that are associated with carcinogenesis indicates that compound 5l has a potent FLT3 inhibition (IC50 = 36.21 ± 1.07 nM). Remarkably, compound 5l was three times more effective as a CDK2 inhibitor (IC50 = 8.17 ± 0.32 nM) compared to sunitinib (IC50 = 27.90 ± 1.80 nM). Compound 5l was further analyzed by means of docking and molecular dynamics simulation for CDK2 and FLT3 active sites which provided a rational for the observed strong inhibition of kinases. These results suggest a novel structural scaffold candidate that simultaneously inhibits CDK2 and FLT3 and gives encouragement for further development as a potential therapeutic for leukemia and colon cancer.

Exploration of (S)-3-aminopyrrolidine As a Potentially Interesting Scaffold for Discovery of Novel Abl and PI3K Dual Inhibitors.

Structurally Novel PI3Kδ/γ Dual Inhibitors Characterized by a Seven-Membered Spirocyclic Spacer: the SARs Investigation and PK Evaluation.

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Design, Synthesis and Biological Evaluation of Novel Selective PI3Kδ Inhibitors Containing Pyridopyrimidine Scaffold.

Biological Evaluation and Structure Modification of (S)-3-aminopyrrolidine Derivatives

Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives As PI3K Inhibitors with Potent Activity.

Exploring Novel PLK1 Inhibitors Based on Computational Studies of 2,4-Diarylaminopyrimidine Derivatives

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-<i>a</i>]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors

Discovery and Synthesis of a Novel Series of Potent, Selective Inhibitors of the PI3Kα: 2-Alkyl-chromeno[4,3-c]pyrazol-4(2h)-one Derivatives.

Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.

Discovery of Pyrazolo[1,5- a ]pyrimidine derivative as a potent and selective PI3Kγ/δ dual inhibitor

Discovery of Pyrazolo[1,5- a ]pyridine Derivatives as Potent and Selective PI3Kγ/δ Inhibitors

Discovery of Novel Quinazoline Derivatives As Potent PI3Kδ Inhibitors with High Selectivity.

Discovery of Novel Bcr-Abl Inhibitors with Diacylated Piperazine As the Flexible Linker

Discovery of Potent and Selective PI3Kδ Inhibitors for the Treatment of Acute Myeloid Leukemia

Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies

Discovery and Anticancer Screening of Novel Oxindole-Based Derivative Bearing Pyridyl Group as Potent and Selective Dual FLT3/CDK2 Kinase Inhibitor

Design, Synthesis and in Vitro Biological Evaluation of 2-Aminopyridine Derivatives As Novel PI3Kδ Inhibitors for Hematological Cancer.

Discovery of potent and selective PI3Kδ inhibitors bearing amino acid fragments